#USA #Los Angeles #Schall Law Firm #Securities Fraud #MoonLake Immunotherapeutics

Investors Alert: Legal Action Against MoonLake Immunotherapeutics

Investors of MoonLake Immunotherapeutics, publicly traded as MLTX, are being informed of a significant opportunity to engage in a class action lawsuit that could lead to substantial recoveries for those affected by alleged securities fraud. The Schall Law Firm, a nationally recognized firm specializing in shareholder rights litigation, is handling the case and urges affected shareholders to come forward. This legal action stems from accusations that MoonLake misled investors about the efficacy of its drug candidate, sonelokimab (SLK).

Background of the Case

Between March 10, 2024, and September 29, 2025, MoonLake made public assertions about SLK, claiming it was demonstrably superior to existing monoclonal antibodies. However, as highlighted in the lawsuit, these claims turned out to be unsubstantiated, with the firm allegedly aware of the lack of evidence supporting its claims. The situation escalated when the results from a Phase 3 trial were disclosed, revealing a significantly poor performance that was dubbed a "disastrous result" by market analysts. Following this revelation, the company's stock plummeted, erasing nearly 90% of its market value, devastating many shareholders.

What Investors Should Do

Investors who acquired MoonLake’s securities during the specified class period are encouraged to contact the Schall Law Firm before the deadline of December 15, 2025. If you have suffered losses as a shareholder, there’s a distinct possibility that you can participate in the lawsuit to reclaim those losses. The Schall Law Firm offers a free, initial consultation regarding your rights and potential participation in the suit.

Contact details for the law firm are as follows:

• - Address: 2049 Century Park East, Suite 2460, Los Angeles, CA 90067
• - Phone: 310-301-3335
• - Website: www.schallfirm.com
• - Email: [email protected]

Understanding Your Rights

It’s important to note that as of now, the class has not yet been certified. Until this certification occurs, individual investors are not represented by an attorney. Those who opt to remain passive in this situation risk being classified as an absent class member, which may impact their ability to recover damages.

The Importance of Acting

Given the circumstances, affected individuals should act promptly. Participating in this lawsuit could be critical in holding MoonLake accountable for its alleged misrepresentations and recovering any financial losses incurred as a result. Legal representation and a strong community of fellow investors can enhance the chances of a successful outcome.

• ---

In conclusion, the ongoing situation highlights the risks involved with investments in pharmaceutical firms and the importance of thorough due diligence before investing. The Schall Law Firm aims to represent the interests of investors and protect their rights against corporate misconduct. Investors should consider joining the lawsuit not only to recover their losses but also to stand up against misinformation in the investment community.